Loading
A phase 3 trial testing HMPL-306 in acute myeloid leukaemia, now recruiting.
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukaemia is a phase 3 interventional study registered as NCT06387069, led by Hutchmed, and recruiting on the registry. Official title: A Multicenter, Randomised, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukaemia (R/R AML). Planned enrolment is 316 participants (estimated). The study started in 2024-04-26 and primary completion is expected in 2028-12-31. No results have been posted on ClinicalTrials.gov.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia.